Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MGD010 in Healthy Volunteers
NCT02376036Phase 1Completed
- Sponsor
- MacroGenics
- Start
- Feb 2015
- Primary completion
- Feb 2017
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PRV-3279 in systemic lupus erythematosus (SLE) and autoimmune diseases (4 arms), sponsored by MacroGenics. Primary endpoint: Safety and Tolerability as assessed by AEs and SAEs. Started Feb 2015; status: completed.
02
Drugs
PRV-3279
03
Conditions
systemic lupus erythematosus (SLE)autoimmune diseases
Beyond the preview
Go deeper on NCT02376036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02376036.